# EDGAR Filing Document

**Accession Number:** 0001615840
**File Stem:** 0001683168-26-001488
**Filing Date:** 2026-3
**Character Count:** 7369
**Document Hash:** c3e255a927b47d91278631b4a059ed32
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-001488.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001683168-26-001488

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260302

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** O'Loughlin Steve
- **CENTRAL INDEX KEY:** 0001615840

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39126
- **FILM NUMBER:** 26722483

**MAIL ADDRESS:**
- **STREET 1:** 955 HARTMAN RUN ROAD
- **CITY:** MORGANTOWN
- **STATE:** WV
- **ZIP:** 26507
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CNS Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001729427
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 822318545
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2100 WEST LOOP SOUTH
- **STREET 2:** SUITE 900
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77027
- **BUSINESS PHONE:** 1-800-946-9185

**MAIL ADDRESS:**
- **STREET 1:** 2100 WEST LOOP SOUTH
- **STREET 2:** SUITE 900
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77027

## Ex-24

**Exhibit 24**

**<u>POWER OF ATTORNEY</u>**

KNOW ALL BY THESE PRESENTS, the undersigned, as a person who is or may become required to file with the Securities and Exchange Commission ("<u>SEC</u>") public reports disclosing their holdings of, and transactions in, the equity securities of CNS Pharmaceuticals, Inc. (the "<u>Company</u>") under Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the "<u>1934 Act</u>"), hereby constitutes and appoints each of Steve O'Loughlin and/or Christopher Downs as the undersigned's true and lawful attorneys-in-fact to:

&nbsp;&nbsp;&nbsp;&nbsp;1. Complete and execute Forms 3, 4 and 5 and other forms required under Section 16 of the 1934 Act and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the 1934 Act and the rules and regulations thereunder, as a consequence of the undersigned's ownership, acquisition or disposition of any equity securities of the Company; and

2. Do and perform any and all acts necessary or incidental to the execution and filing of such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate, including without limitation the authority to execute and file amendments to any previously filed forms.

Each of the attorneys-in-fact named herein shall have the authority to act individually and independently in accordance with this Power of Attorney, and the signature or act of any one of them shall be sufficient. The undersigned hereby ratifies and confirms all that said attorneys-in-fact shall lawfully do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the 1934 Act. The undersigned remains solely responsible for compliance with all requirements under Section 16 and for the accuracy and completeness of all information provided to the attorneys-in-fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact and the Company's Secretary at the Company's principal executive office. This Power of Attorney shall automatically terminate upon the death or incapacity of the undersigned, or upon the death, resignation from the Company, or incapacity of the attorneys-in-fact. If one attorney-in-fact becomes unable to serve, the remaining attorney-in-fact shall continue to have full authority hereunder.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of March, 2026.

Signature: <u>/s/ Steve O'Loughlin</u>

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>O'Loughlin Steve<br><sub>(Last) (First) (Middle)</sub><br>C/O CNS PHARMACEUTICALS, INC.<br>100 WEST LOOP SOUTH, SUITE 900<br><sub>(Street)</sub><br>HOUSTON, TX 77027<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>CNS Pharmaceuticals, Inc. [ CNSP ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-02 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Financial Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Christopher Downs, Attorney-in-fact  
**Date:** 2026-03-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**